challenging. An unrelated donor graft is an alternative option, but it is limited by ethnicassociated disparities, high-costs and a long lag time to procurement. We share our experience in performing T-cell replete haploidentical HSCT (hHSCT) in an infant with T _ NK _ B+ SCID, leading to full immune reconstitution.
The infant was an only child of an ethnic Malay non-consanguineous couple. He was referred at ten months of age due to recurrent pneumonia, chronic diarrhoea and failure to thrive.
His BCG inoculation site was pustular and yielded acid-fast bacilli. Investigations showed markedly reduced T and NK cells with undetectable serum immunoglobulin levels (Table I) . Although the first HSCT to correct SCID was performed nearly 50 years ago,
the optimal transplantation preparative therapy or any at all remains controversial. In this child's case, a reduced-intensity conditioning regimen was chosen to achieve a balance between ensuring engraftment while avoiding a flare-up of his underlying morbidities. T-cell depleted Page 3 of 3 hHSCT is currently the treatment of choice for infants with SCID who lack an HLA-matched donor. (3) However, the high cost and expertise required to engineer the graft preclude this technique in countries with limited resources. Our case illustrates that hHSCT using unmanipulated T-cell replete bone marrow is a feasible method to cure infants with SCID.
Yours sincerely, Hany Ariffin, Kee Seang Chew, Vida Jawin, Surendran Thavagnanam
